Related references
Note: Only part of the references are listed.Human CD14+CTLA-4+ Regulatory Dendritic Cells Suppress T-Cell Response by Cytotoxic T-Lymphocyte Antigen-4-Dependent IL-10 and Indoleamine-2,3-Dioxygenase Production in Hepatocellular Carcinoma
Yanmei Han et al.
HEPATOLOGY (2014)
Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
Susan Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies
Austin Duffy et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
Saskia J. A. M. Santegoets et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
Alfons J. M. van den Eertwegh et al.
LANCET ONCOLOGY (2012)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al.
NATURE MEDICINE (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
Rachel F. Gabitass et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Autoimmunity and treatment outcome in melanoma
Marna G. Bouwhuis et al.
CURRENT OPINION IN ONCOLOGY (2011)
Nomenclature of monocytes and dendritic cells in blood
Loems Ziegler-Heitbrock et al.
BLOOD (2010)
Immune Tolerance Induction by Integrating Innate and Adaptive Immune Regulators
Jun Suzuki et al.
CELL TRANSPLANTATION (2010)
CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions
Stefania Laurent et al.
HUMAN IMMUNOLOGY (2010)
Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b(+)/CD14(-)/CD15(+)/CD33(+) myeloid-derived suppressor cells and CD8(+) T lymphocytes in patients with advanced-stage non-small cell lung cancer
Chien-Ying Liu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immunosuppressive CD14+HLA-DRlow/- Monocytes in Prostate Cancer
Stanimir Vuk-Pavlovic et al.
PROSTATE (2010)
Prostate cancer as a model for tumour immunotherapy
Charles G. Drake
NATURE REVIEWS IMMUNOLOGY (2010)
Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells
Yu Liu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
C. Marcela Diaz-Montero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Jeffrey Weber
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Lawrence Fong et al.
CANCER RESEARCH (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients:: CD1c+ dendritic cell frequency predicts progression-free survival
Hester van Cruijsen et al.
CLINICAL CANCER RESEARCH (2008)
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells
Bastian Hoechst et al.
GASTROENTEROLOGY (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
James C. Yang et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor based antitumor vaccine
Paola Filipazzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells
Rongcun Yang et al.
CANCER RESEARCH (2006)
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer
JW Simons et al.
CLINICAL CANCER RESEARCH (2006)
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells
P Serafini et al.
CANCER RESEARCH (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate
N Boissel et al.
LEUKEMIA (2004)
In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery
PY Pan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Altered maturation of peripheral blood dendritic cells in patients with breast cancer
S Della Bella et al.
BRITISH JOURNAL OF CANCER (2003)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
FS Hodi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer
S Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Characterization of human blood dendritic cell subsets
KPA MacDonald et al.
BLOOD (2002)
6-sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells
K Schäkel et al.
IMMUNITY (2002)
BDCA-2, BDCA-3 and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood
A Dzionek et al.
JOURNAL OF IMMUNOLOGY (2000)
Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles
D Haddad et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
